The Economics of Personalized Medicine

Jan 26, 2011

The Wall Street Journal's Hester Plumridge writes that personalized medicine offers advantages, but also poses challenges for pharmaceutical companies. Giving patients a drug that is known to be effective for their genetic profile not only will lower health care costs and limit adverse reactions, but also, Plumridge says, minimize the number of liability claims filed against pharma companies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Herbert Tabor Dies

The Washington Post reports that Herbert Tabor, who worked at the US National Institutes of Health for 77 years, has died at 101.

Funds to Get Vaccines

The World Bank is seeking approval for a $12 billion plan to provide low-income nations with funds to procure SARS-CoV-2 vaccines, according to Reuters.

A Number on It

Science writes that public health officials and others are debating whether cycle threshold values should be included on SARS-CoV-2 results.

Nucleic Acids Research Studies on 3D SARS-CoV-2 Structures, Human Brain Atlas, More

In Nucleic Acids Research this week: online database of SARS-CoV-2 protein structures, atlas of the human brain, and more.

Menu